Supernus Pharmaceuticals, Inc. (SUPN - Snapshot Report) reported fourth quarter 2012 net loss per share of 51 cents, narrower than the Zacks Consensus Estimate of a loss of 73 cents. In the fourth quarter of 2011, the company earned $2.34 per share. Fourth quarter revenues were $1.1 million, compared with $0.04 million in the year-ago quarter.
Full year 2012 net loss per share was $2.72, narrower than the Zacks Consensus Estimate of a loss of $7.87 and the year-ago loss of $16.6 per share. Revenues in 2012 were $1.5 million, compared with $0.8 million in 2011.
In the fourth quarter of 2012 research and development expenses were $5.2 million, compared with $7.5 million in the year-ago quarter. The decrease was attributable to lower costs incurred on its antiepileptic drug Oxtellar XR in the final quarter of 2012.
In Feb 2013, Supernus announced the launch of, Oxtellar XR, in the US. Oxtellar XR was approved by the US Food and Drug Administration (FDA) in Oct 2012. In Nov 2012, Supernus received three years of marketing exclusivity from the FDA.
We note that Trokendi XR is another epilepsy drug in Supernus’ portfolio. The drug received tentative FDA approval in Jun 2012. Supernus intends to launch the drug in the third quarter of 2013. In Oct 2012, United States Patent and Trademark Office (USPTO) issued two patents to cover Trokendi XR.
In the fourth quarter of 2012, selling, general and administrative (SG&A) were $8.7 million, compared with $2.8 million in the year-ago quarter. The increase was due to higher sales and marketing expenses.
In Nov 2012, Supernus had announced encouraging top-line results from a phase IIb study on SPN-810, across three doses. SPN-810 is being developed for the treatment of impulsive aggression in attention deficit hyperactivity disorder patients.
Cash burn for 2013 is expected in the range $95 million to $105 million.
Supernus carries a Zacks Rank #3 (Hold). Currently, companies like Lannett Company, Inc. (LCI - Snapshot Report), WuXi Pharma Tech (Cayman) Inc. and QLT Inc. (QLTI - Analyst Report) look more attractive in the pharma space. All three stocks carry a Zacks Rank #1 (Strong Buy).